Home » Biosciences » Molecular Biology » Pecorino: Molecular Biology of Cancer 2e » Student resources » Hyperlinked bibliography » Chapter 04
Pecorino: Molecular Biology of Cancer 2e
Chapter 04
Further reading
Bennasroune, A., Gardin, A., Aunis, D., Cremel, G., and Hubert, P. (2004) Tyrosine kinase receptors as attractive targets of cancer therapy. Crit. Rev. Oncol. Hematol. 50: 23-38. [PubMed: 15094157] [DOI: 10.1016/j.critrevonc.2003.08.004]
Blume-Jensen, P. and Hunter, T. (2001) Oncogenic kinase signaling. Nature 411: 355-365. [PubMed: 11357143] [DOI: 10.1038/35077225]
Downward, J. (2003) Targeting ras signalling pathways in cancer therapy. Nature Rev. Cancer 3: 11-22. [DOI: 10.1038/nrc969]
Druker, B.J. (2002) STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med. 8: S14-S18. [PubMed: 11927282] [DOI: 10.1016/S1471-4914(02)02305-5]
Krause, D.S. and Van Etten, R.A. (2005) Tyrosine kinases as targets for cancer therapy. N Engl J. Med. 353: 172-187. [DOI: 10.1056/NEJMra044389]
Linggi, B. and Carpenter, G. (2006) ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 16: 649-656. [PubMed: 17085050] [DOI: 10.1016/j.tcb.2006.10.008]
Sawyers, C.L. (2002) Rational therapeutic intervention in cancer: kinases as drug targets. Current Opin. Genet. Dev. 12: 111-115. [DOI: 10.1016/S0959-437X(01)00273-8]
Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. Cell 103: 211-225. [PubMed: 11057895] [DOI: 10.1016/S0092-8674(00)00114-8]
Schlessinger, J. (2002) Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110: 669-672. [PubMed: 12297041] [DOI: 10.1016/S0092-8674(02)00966-2]
Yeatman, T.J. (2004) A renaissance for Src. Nature Rev. Cancer 4: 470-480. [DOI: 10.1038/nrc1366]
Zandi, R., Larsen, A.B., Andersen, P., Stockhausen, M.-T., and Poulsen, H.S. (2007) Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. 19: 2013-2023. [PubMed: 17681753] [DOI: 10.1016/j.cellsig.2007.06.023]
Zwick, E., Bange, J., and Ullrich, A. (2002) Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol. Med. 8: 17-23. [PubMed: 11796262] [DOI: 10.1016/S1471-4914(01)02217-1]
Selected Special Topics
Chang, E.H., Furth, M.E., Scolnick, E.M., and Lowy, D.R. (1982) Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature 297: 479-483. [PubMed: 6283358] [DOI: 10.1038/297479a0]
Gonzalez-Sancho, J.M., Garcia, V., Bonilla, F., and Munoz, A. (2003) Thyroid hormone receptors/THR genes in human cancer. Cancer Lett. 192: 121-132. [PubMed: 12668276] [DOI: 10.1016/S0304-3835(02)00614-6]
Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Nagesh Rao, P., and Sawyers, C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880. [DOI: 10.1126/science.1062538]
Hingorani, S.R. and Tuveson, D.A. (2003) Ras redux: rethinking how and where Ras acts. Curr. Opin. Genet. Dev. 13: 6-13. [PubMed: 12573429] [DOI: 10.1016/S0959-437X(02)00017-5]
Ise, K., Nakamura, K., Nakao, K., Shimizu, S., Harada, H., Ichise, T., Miyoshi, J., Gondo, Y., Ishikawa, T., Aiba, A., and Katsuki, M. (2000) Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene 19: 2951-2956. [PubMed: 10871846] [DOI: 10.1038/sj.onc.1203600]
Pao, W., Miller, V.A., and Kris, M.G. (2004) Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin. Cancer Biol. 14: 33-40. [PubMed: 14757534] [DOI: 10.1016/j.semcancer.2003.11.005]
Reddy, E.P., Reynolds, R.K., Santos, E., and Barbacid, M. (1982) A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300: 149-152. [PubMed: 7133135] [DOI: 10.1038/300149a0]
Schindler, T., Bornmann, W., Pellicena, Miller, W.T., Clarkson, B., and Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289: 1938-1942. [PubMed: 10988075] [DOI: 10.1126/science.289.5486.1938]
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., Schwartz, B., Simantov, R., and Kelley, S. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Rev. Drug Discovery 5: 835-844. [DOI: 10.1038/nrd2130]